Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations

PURPOSE: Most epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are resistant to tyrosine kinase inhibitors (TKIs). While some non-small cell lung cancer (NSCLC) patients harboring special subtypes of EGFR ex20ins still achieved clinical response after TKIs treatment, ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ling, Wu, Xiaomai, Yan, Shuangquan, Zhu, Yefei, Yan, Zhengqing, Lv, Dongqing, Ge, Hongfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533245/
https://www.ncbi.nlm.nih.gov/pubmed/33061454
http://dx.doi.org/10.2147/OTT.S268694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533245/
https://www.ncbi.nlm.nih.gov/pubmed/33061454
http://dx.doi.org/10.2147/OTT.S268694

Ejemplares similares